APLIF (Appili Therapeutics) Total Stockholders Equity: $-12.63 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Appili Therapeutics Total Stockholders Equity?

Appili Therapeutics APLIF Total Stockholders Equity is $-12.63 Mil as of Mar. 2026. The stock has 2 warning signs investors should review.

Appili Therapeutics's Total Stockholders Equity for the quarter that ended in Mar. 2026 was $-12.63 Mil. It refers to the net assets owned by shareholders. It does not include minority interest.

Total Stockholders Equity is used to calculate Book Value per Share. Appili Therapeutics's Book Value per Share for the quarter that ended in Mar. 2026 was $-0.10. The ratio of a company's debt over equity can be used to measure how leveraged this company is. Appili Therapeutics's Debt-to-Equity for the quarter that ended in Mar. 2026 was -0.75.


Appili Therapeutics  (OTCPK:APLIF) Total Stockholders Equity Explanation

1. Total Stockholders Equity is used to calculate Book Value per Share.

Appili Therapeutics's Book Value per Share for the quarter that ended in Mar. 2026 is

2. The ratio of a company's debt over equity can be used to measure how leveraged this company is.

Appili Therapeutics's Debt-to-Equity for the quarter that ended in Mar. 2026 is

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Appili Therapeutics Total Stockholders Equity Related Terms


Appili Therapeutics Total Stockholders Equity Historical Data

* Premium members only.

The historical data trend for Appili Therapeutics's Total Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Appili Therapeutics Total Stockholders Equity Chart

Appili Therapeutics Annual Data
Trend Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Total Stockholders Equity
Get a 7-Day Free Trial Premium Member Only -2.58 -5.41 -8.07 -9.33 -12.63

Appili Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Stockholders Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -9.33 -10.70 -11.28 -11.88 -12.63
What does a Total Stockholders Equity of $-12.63 Mil mean?
Appili Therapeutics (APLIF) has a Total Stockholders Equity of $-12.63 Mil as of Mar. 2026. The total amount of shareholder's equity as recorded on a company's balance sheet. View historical data for Appili Therapeutics and its competitors.
Is Appili Therapeutics' Total Stockholders Equity too high?
Appili Therapeutics' current Total Stockholders Equity is $-12.63 Mil.
How does Appili Therapeutics' Total Stockholders Equity compare to VRTX and REGN?
Appili Therapeutics' Total Stockholders Equity of $-12.63 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Stockholders Equity for a Biotechnology company?
A good Total Stockholders Equity depends on the Biotechnology industry context. However, Total Stockholders Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Stockholders Equity mean?
A high Total Stockholders Equity can signal that a stock is expensive relative to its fundamentals. The total amount of shareholder's equity as recorded on a company's balance sheet. View historical data for Appili Therapeutics and its competitors. Appili Therapeutics's current Total Stockholders Equity is $-12.63 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Appili Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Appili Therapeutics (APLIF) is currently considered Fairly Valued. The stock's GF Value™ is $0.01, compared to a current price of $0.01 — trading 10% above its estimated fair value. The current Total Stockholders Equity is $-12.63 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Stockholders Equity calculated?
Total Stockholders Equity is calculated from a company's financial statements. For Appili Therapeutics (APLIF), the current Total Stockholders Equity is $-12.63 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Appili Therapeutics Business Description

Other Exchanges APLI:Canada
Address 1344 Summer Street, Suite 21, Halifax, NS, CAN, B3H 0A8
Appili Therapeutics Inc is a biopharmaceutical company. The company is engaged in novel antibiotic and anti-infective therapies to help patients suffering from serious infections. Its anti-infective portfolio currently includes programs namely ATI-1701, ATI-1801.